Sanofi-aventis and Metabolex said that GPR119 receptor agonists (or G-protein coupled receptor 119) are known to exert the effects on glucose metabolism by a dual mode of action affecting both insulin and GLP-1 (glucagon-like peptide-1) release.
Sanofi-aventis and Metabolex stated that MBX-2982 is expected to offer improved glucose control when compared withexisting oral diabetes therapies, with an additional weight benefit.
As per the agreement terms, Sanofi-aventis is expected to receive an exclusive license to develop, manufacture and commercialise MBX-2982, which is in Phase II a, and related compounds.
Metabolex is expected to receive an upfront payment and is also expected to be eligible to receive development, regulatory, and specified commercial milestone payments.
Additionally, Metabolex will also receive royalties on the product sales. The license agreement is subject to antitrust clearance in the US under the Hart-Scott-Rodino Act.
Pierre Chancel, senior vice-president of global diabetes at Sanofi-aventis, said: “The new mechanism of action of MBX-2982 is promising and we are excited to have identified Metabolex as our partner.”